Saturday 21 December 2024

The Pharma Letter Podcast — Episode 13 — Is there a data capture crisis in biotech?

Biotechnology
Simon Wentworth
5 April 2022
thepharmaletterpodcast-episode13-1

More on this story...

Pharmaceutical
Increasing number of ATPM clinical trials in the UK
17 January 2023
Biotechnology
The Pharma Letter Podcast — Episode 9 — The rise of AI in drug discovery
30 December 2021
Pharmaceutical
The Pharma Letter Podcast — Episode 10 — Will decentralized clinical trials become the new standard?
10 February 2022
Biotechnology
Major entrant in biotech discovery could shake up existing order
6 May 2022


More ones to watch >


Today's issue

Neurocrine Biosciences launches Crenessity in USA
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024
Pharmaceutical
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Biotechnology
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024
Biotechnology
Novartis to shut MorphSys sites amid pelabresib delay
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Biotechnology

Epitopea teams up with Genevant in $124 million deal
20 December 2024
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Regeneron advances anticoagulant antibody program
20 December 2024
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze